Bromazolam
Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
Bromazolam
(none — never marketed)
Bromazolam is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently miss bromazolam — confirmatory LC-MS/MS is required for reliable detection.
Non-selective positive allosteric modulator at the benzodiazepine site of GABAA receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.
In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is insensitive to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does not reverse bromazolam itself but reverses concurrent opioid depression).
Alprazolam, Clonazolam, Flualprazolam, Etizolam, Flumazenil, Fentanyl, Xylazine, Naloxone
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
None approved. Has no recognized medical role.
+ Add a problemTitration strategies
No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, any illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
Effects
Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
Pharmacokinetics
Pharmacodynamics
Interactions
No interactions reported yet.
- Opioids (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.
- Alcohol, GHB, barbiturates, gabapentinoids: additive CNS/respiratory depression.
- Xylazine: frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
- CYP3A4 inhibitors (azoles, macrolides, ritonavir, grapefruit): prolong/intensify effect.
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort): may reduce levels.
- Flumazenil reverses GABAA effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
Pregnancy and lactation
Monitoring
Patient counseling
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
- DEA Diversion. Bromazolam. Medicine & Chemical Evaluation Section, 2023.
- Papsun DM, et al. Forensic toxicology of bromazolam. J Anal Toxicol 2022.
- CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
- Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated medicine supply.
Summary
Classes
Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
Common uses
No approved medical indication. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
Pharmacy
Starting dose
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
Preparations
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
US FDA Max
N/A (never approved)
Pharmacology
Routes
Oral, sublingual, intranasal; rectal and IV reported.
Onset
~20–40 min PO; faster sublingual/intranasal.
Duration
6–10 h subjective; full pharmacologic effect considerably longer.
Half-life
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
Bioavailability
Not formally characterized in humans.
Pregnancy
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
Legal status
First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a medicine of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
Purported mechanism
Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site; increases frequency of Cl− channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.